Morton Plant Hospital in Clearwater, Florida in the Tampa Bay region has signed up to participate in a clinical trial evaluating novel Alzheimer’s disease detection method. The goal is to drastically impact the lives of thousands of people and family members dealing...
Neurodegenerative Disease
Category
University of Aberdeen Participates in Huntington’s Disease Study and Patient’s Focuses on the Good
The University of Aberdeen, led by Zosia Miedzybrodzka, cares for Huntington’s disease (HD) patients, such as Sandy Patience of Scotland, as the 801 patient global study known as Generation-HD1 unfolds. Patience inherited this condition and declared the clinical...
Cutting-Edge Clinical Trial to Test Retinal Screening as Process for Early Detection of Alzheimer’s Disease
The University of Rhode Island, Florida’s BayCare Health System, and the Memory and Aging Program at Butler Hospital are launching a clinical trial with profound implications: what if a standard eye examination inclusive of a retinal scan could detect biomarkers...
The Dementia Treatment Mission Moves into a New Decade in the UK and Beyond
Unsuccessful drug trials, insufficient funding, and patients too ill to participate in trials spell trouble for the war against dementia. The degradation, struggle and cost in the UK (as well as America and elsewhere) will rise exponentially. The Daily...
The New Chinese Alzheimer’s Drug (GV-971) Making its Way to Global Trials: Material Science or Marketing?
Is the world ready for GV-971(Oligomannate)? Because the first new approved Alzheimer’s drug in many years is coming to a clinical trial near you. Conditionally approved by China’s regulators, many in the West are skeptical. However, industry sponsor Green Valley...
UCSF-Led Study Reveals Tau Superior to Amyloid in Predicting Impacts on Brain Tissue Involving Alzheimer’s Disease
Research from the UC San Francisco (UCSF) Memory and Aging Center in collaboration with UC Berkeley and Lawrence Livermore Laboratory reveals that brain imaging of pathological tau-protein (“tangles”) reliably predicts the location of future brain atrophy in...
Institute for Molecular Medicine on a Mission to Develop Alzheimer’s Vaccine Developed at Flinders University
A research team, including the Institute for Molecular Medicine and the University of California, Irvine (UCI), are in pursuit of a potential preventative treatment for dementia, which may proceed to clinical trials after successful preclinical research (animal...
UCSD Announces Alzheimer’s Disease Research Breakthrough: Obj-SCD Predicts Amyloid Accumulation & Neurodegeneration
University of California, San Diego School of Medicine, and Veterans Affairs San Diego Healthcare System researchers report discovering that the accumulation of amyloid, the abnormal protein linked to neurodegenerative conditions such as Alzheimer’s disease (AD),...
George Washington University Study Asks: Can Nilotinib be Repurposed from use for Specific Cancer to use for Parkinson’s Disease?
There is tremendous value in identifying new purposes for existing drugs. Recently, Georgetown University Medical Center (GUMC) embarked on a project to do just that for Parkinson’s disease with a cancer drug called nilotinib (Tasigna). They found that the drug in...
Stanford Researchers Study Reveals Need for Better Understanding of Clinical Trial Risks
Stanford University researchers study concludes that clinical trials can offer patients with Huntington’s disease (HD) hope when there are no treatments available despite unknowns whether the therapy will work or is safe. The study results show that although the HD...
ADDF Invests $3m in Vaccinex Contingent for Alzheimer’s Disease Contingent on IRB Approval & Enrollment Milestones
The Alzheimer’s Drug Discovery Foundation (ADDF) has granted an award, in the form of an investment of up to approximately $3 million in Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and...
Northwestern University Center for Neurogenetics Developed S-181 Evidences Promise for Addressing Parkinson’s Disease
Researchers from the Center for Neurogenetics and colleagues from the Northwestern University Feinberg School of Medicine report a novel small-molecule modulator called S-181 shows promise in preclinical research animal studies for the treatment of a familial form of...
The Alzheimer’s Drug Discovery Foundation Invests $6m in Six Studies in Pursuit of Early AD Detection
The Alzheimer’s Drug Discovery Foundation (ADDF) has invested $6 million in six investments via its Diagnostics Accelerator initiative. Specific research awards include studies involving blood tests in various stages of development including one that could become a...
University of Toronto Study Highlights Protein Variability with Neurodegenerative Disease
A new University of Toronto study highlights how protein strains vary in the brains of those affected by progressive neurodegenerative diseases such as Parkinson’s suggesting a growing recognition of the need for patient-specific medicines. Published in...
TauRX Keeps Pushing Forward With LMTM for Alzheimer’s Disease Despite Skepticism
Singapore-based TauRX is progressing its experimental medicine known as “LMTM” to advanced Phase III clinical trials in America and Europe based on the results of two previous Phase III studies evidencing the potential promise as a treatment for Alzheimer’s disease....
Beaumont Research Institute Sponsored Trial Assesses Use of Low Dose Radiation to Treat Alzheimer’s
Clinical investigators from the Beaumont Research Institute in Royal Oak, Michigan suspects low-dose radiation may represent a promising treatment for Alzheimer’s disease. Presently seeking participants, this study will assess the use of low dose fractionalized whole...
Researchers Report Growing Gene Therapy Momentum in Neurodegenerative Drug Development Field
Gene therapy is making a comeback in the world of neurodegeneration research, as evidenced by this year’s Society for Neuroscience conference held in Chicago. With the success of Novartis Zolgensma (gene therapy for spinal muscular atrophy in infants), money...
UCSF Memory & Aging Center Conduct Basket Trials to Explore Acceleration of Neurodegenerative Disease Drug Development
The UC San Francisco Memory and Aging Center (MAC) has developed a new type of clinical trial for dementia aiming to accelerate treatments for neurodegenerative disease. By adapting one of the precision medicine approaches that have defined 21st century cancer...
Researchers at Stanford Discover Common Denominator In Several Neurodegenerative Diseases
Investigators at the Stanford University School of Medicine have found, in both mouse brain models and human brain cultures, that Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, or Lou Gehrig’s disease, share a common mode of damaging...
Investigators Identify Possible Diagnostic Tool & Treatment for Parkinson’s Disease
Investigators at the Stanford University School of Medicine have identified a molecular defect that appears to be universal to Parkinson’s disease as well as those at risk of becoming afflicted with the neurodegeneration disease. This discover may pave the way...